Document Detail

Successful progressive challenge after a cutaneous reaction to imatinib mesylate (Gleevec): a case report and review of the literature.
MedLine Citation:
PMID:  15603208     Owner:  NLM     Status:  MEDLINE    
The use of imatinib mesylate (Gleevec), a selective tyrosine kinase inhibitor, has become the new gold standard for the treatment of chronic myeloid leukemia. Unfortunately, the medication has been commonly associated with mild to severe cutaneous reactions, which has limited its use for some patients. We describe a case of a successful progressive challenge of a patient with a drug-induced exanthem from imatinib mesylate and a review of the literature.
Miguel A Park; Gerald W Volcheck; Juan C Guarderas
Related Documents :
7593568 - Vertebral collapse in childhood leukemia.
16938568 - Translocation (10;11)(p12;q23) in childhood acute myeloid leukemia: incidence and compl...
19641858 - Chronic myeloid leukemia patient manifesting fatal hepatitis b virus reactivation durin...
3422168 - Tdt expression in acute myeloid leukaemia. haemopoietic immaturity or maturational asyn...
10811028 - Treatment of chyloperitoneum after extended lymphatic dissection during duodenopancreat...
1658118 - Pacinian corpuscle hyperplasia in the hand.
Publication Detail:
Type:  Case Reports; Journal Article; Review    
Journal Detail:
Title:  Allergy and asthma proceedings : the official journal of regional and state allergy societies     Volume:  25     ISSN:  1088-5412     ISO Abbreviation:  Allergy Asthma Proc     Publication Date:    2004 Sep-Oct
Date Detail:
Created Date:  2004-12-17     Completed Date:  2005-02-22     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  9603640     Medline TA:  Allergy Asthma Proc     Country:  United States    
Other Details:
Languages:  eng     Pagination:  345-7     Citation Subset:  IM    
Division of Allergic Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / adverse effects*
Desensitization, Immunologic*
Drug Eruptions / etiology,  therapy*
Exanthema / chemically induced*,  therapy*
Middle Aged
Piperazines / adverse effects*
Pyrimidines / adverse effects*
Reg. No./Substance:
0/Antineoplastic Agents; 0/Piperazines; 0/Pyrimidines; 152459-95-5/imatinib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Fexofenadine HCl 60 mg/ pseudoephedrine HCl 120 mg has a 60-minute onset of action in the treatment ...
Next Document:  UV radiation-induced immunosuppression and skin cancer.